Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
13.53
-0.13 (-0.95%)
At close: May 22, 2026, 4:00 PM EDT
13.32
-0.21 (-1.56%)
After-hours: May 22, 2026, 7:13 PM EDT
Relay Therapeutics Revenue
Relay Therapeutics had revenue of $3.00M in the quarter ending March 31, 2026, a decrease of -60.93%. This brings the company's revenue in the last twelve months to $10.68M, up 39.04% year-over-year. In the year 2025, Relay Therapeutics had annual revenue of $15.36M with 53.44% growth.
Revenue (ttm)
$10.68M
Revenue Growth
+39.04%
P/S Ratio
276.20
Revenue / Employee
$55,316
Employees
193
Market Cap
2.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.36M | 5.35M | 53.44% |
| Dec 31, 2024 | 10.01M | -15.54M | -60.83% |
| Dec 31, 2023 | 25.55M | 24.17M | 1,749.82% |
| Dec 31, 2022 | 1.38M | -1.65M | -54.41% |
| Dec 31, 2021 | 3.03M | -79.63M | -96.34% |
| Dec 31, 2020 | 82.65M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 670.00M |
| Arcutis Biotherapeutics | 415.62M |
| IDEAYA Biosciences | 225.27M |
| Nektar Therapeutics | 55.63M |
| Immunome | 4.02M |
| Celldex Therapeutics | 865.00K |
RLAY News
- 1 day ago - Relay Therapeutics 22.9M share Secondary priced at $12.00 - TheFly
- 1 day ago - Relay Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 2 days ago - Relay Therapeutics price target raised to $21 from $19 at Citizens - TheFly
- 2 days ago - Relay Therapeutics price target raised to $27 from $21 at Barclays - TheFly
- 3 days ago - Relay Therapeutics announces $175M common stock offering - TheFly
- 3 days ago - Relay Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 3 days ago - Relay Therapeutics upgraded at JonesResearch after zovegalisib data - TheFly
- 3 days ago - Relay Therapeutics upgraded to Buy from Hold at JonesResearch - TheFly